| 000 | 01798 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250515232829.0 | ||
| 264 | 0 | _c20101206 | |
| 008 | 201012s 0 0 eng d | ||
| 022 | _a1940-6215 | ||
| 024 | 7 |
_a10.1158/1940-6207.CAPR-09-0261 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZhang, Jinhui | |
| 245 | 0 | 0 |
_aProteomic profiling of potential molecular targets of methyl-selenium compounds in the transgenic adenocarcinoma of mouse prostate model. _h[electronic resource] |
| 260 |
_bCancer prevention research (Philadelphia, Pa.) _cAug 2010 |
||
| 300 |
_a994-1006 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdenocarcinoma _xdrug therapy |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aBiomarkers, Pharmacological _xanalysis |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xanalysis |
| 650 | 0 | 4 |
_aCysteine _xanalogs & derivatives |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMetabolome _xdrug effects |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred C57BL |
| 650 | 0 | 4 | _aMice, Transgenic |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 |
_aOrganoselenium Compounds _xpharmacokinetics |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aProteomics _xmethods |
| 650 | 0 | 4 |
_aSelenium Compounds _xpharmacokinetics |
| 650 | 0 | 4 |
_aSelenocysteine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aSelenomethionine _xpharmacokinetics |
| 700 | 1 | _aWang, Lei | |
| 700 | 1 | _aAnderson, Lorraine B | |
| 700 | 1 | _aWitthuhn, Bruce | |
| 700 | 1 | _aXu, Yanji | |
| 700 | 1 | _aLü, Junxuan | |
| 773 | 0 |
_tCancer prevention research (Philadelphia, Pa.) _gvol. 3 _gno. 8 _gp. 994-1006 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1158/1940-6207.CAPR-09-0261 _zAvailable from publisher's website |
| 999 |
_c19988315 _d19988315 |
||